$13.240
-0.482 (-3.64%)At close
ORIC News
ORIC Events
ORIC Initiates Himalayas-1 Trial, Advancing Prostate Cancer Treatment
"The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially practice-changing therapy for patients with prostate cancer," said Jacob M. Chacko, president and chief executive officer. "With rinzimetostat now in Phase 3 and enozertinib approaching a key clinical update in the second half of the year, ORIC has become a diversified, late-stage oncology company with multiple opportunities to create meaningful value for patients while advancing our mission of Overcoming Resistance In Cancer."
Oric Pharmaceuticals Initiates Himalayas-1 Trial
Oric Pharmaceuticals (ORIC) announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone and announced a clinical trial collaboration and supply agreement with Bayer (BAYRY).
ORIC Selects Phase 3 Dose for Rinzimetostat, Moves Toward Registrational Trial
"The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat, reported data supporting a potential best-in-disease profile, and moved toward the initiation of Himalayas-1, our first registrational trial," said Jacob M. Chacko, president and chief executive officer. "With a strong cash position and multiple enozertinib clinical updates expected later this year, we see a clear path to building ORIC into a multi-asset, late-stage oncology company."
ORIC Pharmaceuticals Presents Rinzimetostat's Potential in Prostate Cancer
ORIC Pharmaceuticals "announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annual Meeting highlighting the potential of rinzimetostat. or ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC's website here." "Our research continues to show the therapeutic potential of PRC2 inhibition across the prostate cancer disease spectrum, by reducing tumor adaptability and sustaining the benefit derived from androgen-receptor targeted therapies," said Lori Friedman, PhD, chief scientific officer. "Additionally, our preclinical studies reveal that targeting PRC2 via EED has potential advantages over targeting EZH2, which, together with the clinical data generated to date, furthers our conviction that rinzimetostat is a potential best-in-class PRC2 inhibitor."
Major Averages Close Broadly Higher as Market Sentiment Improves
The major averages closed broadly higher, extending the strength of the last day of March into the start of April. Markets are staging a sharp relief rally as the dominant narrative is de-escalation. Comments suggesting a potential wind-down of U.S. military activity in Iran have triggered a broad risk-on move across equities, bonds and currencies. Of note, President Trump said in a social media post that Iran's president has requested a ceasefire, though Trump noted the U.S. will consider the offer when the Strait of Hormuz is "open, free, and clear."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nikereportedbut guided for a decline in Q3 revenueRHreportedand revenue and provided FY26 and FY27 revenue growth guidanceIntelwillin its Ireland Fab joint venture with Apollo GlobalAn Iranian strike damaged an Amazoncloud computing operation in Bahrain a day after Iran's Revolutionary Guards threatened to target U.S. companies operating in the Middle East, including Microsoft, Apple, Google, Meta, and others,General Motorsreported aand Stellantis'FCA reported a 4% increase while Toyotareported an 8.5% decline in March sales in the U.S.2. WALL STREET CALLS:JPMorgan, BofA and Goldman SachsNike after fiscal Q3 reportDisneyto Outperform at Raymond JamesRaymond James alsoUnitedHealthto OutperformDA DavidsonRivianto Neutral on valuation post selloffPPGto Neutral at Citi on raw material costs3. AROUND THE WEB:Stellantisis in talks to build electric vehicles in Canada with a Chinese partner, Bloomberg saysRelated Digital is finalizing $16B in financing for an Oracledata center in Michigan to support OpenAI workloads, Bloomberg reportsAppleis testing letting Siri process multiple requests in a single query in iOS 27, Bloomberg saysTesla'sQ1 deliveries are expected to be lower than December's quarter due to uneven demand and intensifying competition in key markets, Reuters reportsShellis in advanced discussions with Venezuela's government to develop four areas near Trinidad and Tobago, in two areas that are the country's largest offshore natural gas fields, Reuters says4. MOVERS:Target Hospitalityincreased after securing an overDave & Buster'sgained afterand providing guidance for FY26Eli Lillyrose after the FDA approved itsOric Pharmaceuticalswas lower after announcing aGevofell after appointing Kyle James asand Dave Kettner as General Counsel5. EARNINGS/GUIDANCE:Conagra Brandsreportedand narrowed its FY26 earnings outlookPVH, with CEO Stefan Larsson commenting, "We delivered a strong fourth quarter and finish to the year, driven by the strength of our two iconic global brands"Lamb Westonand narrowed its guidance for FY26FitLife, with EPS lower year-over-yearUniFirst, with EPS missing consensusINDEXES:The Dow rose 224.23, or 0.48%, to 46,565.74, the Nasdaq gained 250.32, or 1.16%, to 21,840.95, and the S&P 500 advanced 46.80, or 0.72%, to 6,575.32.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。